Revolution Medicines (RVMD) Capital Expenditures (2019 - 2026)

Revolution Medicines' Capital Expenditures history runs 8 years deep, the most recent figure standing at $786000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 71.78% year-over-year to $786000.0 in Q1 2026; TTM through Mar 2026 was $14.0 million, a 211.88% increase from a year earlier, with the FY2025 full-year figure at $16.0 million, up 914.59% from the prior year.
• Capital Expenditures retreated to $786000.0 in Q1 2026 per RVMD's latest filing, from $3.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $7.9 million in Q2 2025 and bottomed at -$7.5 million in Q4 2024.
• The 5-year median for Capital Expenditures is $1.3 million (2023), against an average of $1.4 million.
• Across the five-year window, Capital Expenditures plunged 452.47% in 2023 and surged 2328.0% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at -$507000.0 in 2022, then plunged by 452.47% to -$2.8 million in 2023, then slumped by 168.12% to -$7.5 million in 2024, then soared by 143.57% to $3.3 million in 2025, then sank by 75.98% to $786000.0 in 2026.
• Per Business Quant, the three latest RVMD Capital Expenditures figures stand at $786000.0 (Q1 2026), $3.3 million (Q4 2025), and $2.0 million (Q3 2025).